Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)
Conditions
Interventions
Certolizumab Pegol
Certolizumab Pegol
Locations
35
United States
Phoenix, Arizona, United States
Los Angeles, California, United States
Orange, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Hartford, Connecticut, United States
Start Date
April 1, 2009
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2012
Last Updated
August 7, 2018
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07385131
Lead Sponsor
UCB Celltech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions